These tumors are less likely to spread to surrounding tissues than higher-grade tumors, so they often have better outcomes. In the past, pediatric gliomas were classified into low-grade and high-grade ...

In this second installment of MedPage Today's virtual roundtable series on pediatric low-grade glioma, moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, is joined once ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on pediatric low-grade glioma. Moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, ...

Vorasidenib reduced the risk of disease progression or death for certain patients with low-grade brain cancer, recent study results showed. Patients with grade 2 IDH-mutant glioma (a type of brain ...

Please provide your email address to receive an email when new articles are posted on . Maximal resection of low-grade glioma shortly after diagnosis may lead to longer survival, according to research ...

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based on evidence from the INDIGO clinical trial, a global ...

Pediatric low-grade gliomas (pLGGs) represent the most common central nervous system tumours in children, encompassing WHO grade I and II neoplasms with generally indolent behaviour. The prototypical ...

For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise ...

If your child has been diagnosed with a pediatric low-grade glioma (pLGG), you may be wondering where, exactly, you should go for medical care. For starters, you’ll want to look for a treatment center ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...